Nitric oxide synthase inhibition attenuates l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

Neuroscience

Volumn 159, Issue 3, 2009, Pages 927-935

  Padovan Neto, F E ^a   Echeverry, M B ^a   Tumas, V ^a   Del Bel, E A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

6 hydroxydopamine; abnormal involuntary movements; dyskinesia; l DOPA; nitric oxide synthase inhibitors

Indexed keywords

7 NITROINDAZOLE; BENSERAZIDE PLUS LEVODOPA; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DYSKINESIA; ENZYME INHIBITION; LOW DRUG DOSE; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; ENZYME INHIBITORS; INDAZOLES; LEVODOPA; MALE; MOTOR ACTIVITY; NITRIC OXIDE SYNTHASE; NITROARGININE; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA;

EID: 62349123821     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.01.034     Document Type: Article

References (77)

1. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 (2001) 448-458
2. Ashina M., Bendtsen L., Jensen R., Lassen L.H., Sakai F., and Olesen J. Possible mechanisms of action of nitric oxide synthase inhibitors in chronic tension-type headache. Brain 122 (1999) 1629-1635
3. Bara-Jimenez W., Bibbiani F., Morris M.J., Dimitrova T., Sherzai A., Mouradian M.M., and Chase T.N. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 20 (2005) 932-936
4. Bibbiani F., Oh J.D., Kielaite A., Collins M.A., Smith C., and Chase T.N. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol 196 (2005) 422-429
5. Bibbiani F., Oh J.D., and Chase T.N. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57 (2001) 1829-1834
6. Blanchet P.J., Konitsiotis S., and Chase T.N. Amantidine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13 (1998) 798-802
7. Bredt D.S., and Snyder S.H. Nitric-oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci U S A 86 (1989) 9030-9033
8. Brenman J.E., Chao D.S., Gee S.H., McGee A.W., Craven S.E., Santillano D.R., Wu Z.Q., Huang F., Xia H.H., Peters M.F., Froehner S.C., and Bredt D.S. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha 1-syntrophin mediated by PDZ domains. Cell 84 (1996) 757-767
9. Brotchie J.M., Lee J., and Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm 112 (2005) 359-391
10. Calabresi P., Gubellini P., Centonze D., Sancesario G., Morello M., Giorgi M., Pisani A., and Bernardi G. A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression. J Neurosci 19 7 (1999) 2489-2499
11. Carey R.J. Chronic L-DOPA treatment in the unilateral 6-OHDA rat-evidence for behavioral sensitization and biochemical tolerance. Brain Res 568 (1991) 205-214
12. Carreau A., Duval D., Poignet H., Scatton B., Vige X., and Nowicki J.P. Neuroprotective efficacy of n-Omega-Nitro-l-arginine after focal cerebral-ischemia in the mouse and inhibition of cortical nitric-oxide synthase. Eur J Pharmacol 256 (1994) 241-249
13. Carta M., Lindgren H.S., Lundblad M., Stancampiano R., Fadda F., and Cenci M.A. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 96 (2006) 1718-1727
14. Cenci M.A., and Lindgren H.S. Advances in understanding L-DOPA-induced dyskinesia. Curr Opin Neurobiol 17 (2008) 665-671
15. Cenci M.A., and Lundblad M. Post-versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 99 (2006) 381-392
16. Cenci M.A., Whishaw I.Q., and Schallert T. Animal models of neurological deficits: how relevant is the rat?. Nat Rev Neurosci 3 (2002) 574-579
17. Cenci M.A., Tranberg A., Andersson M., and Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-DOPA treatment. Neuroscience 94 (1999) 515-527
18. Cenci M.A., Lee C.S., and Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10 (1998) 2694-2706
19. Centonze D., Gubellini P., Pisani A., Bernardi G., and Calabresi P. Dopamine, acetylcholine and nitric oxide systems interact to induce corticostriatal synaptic plasticity. Rev Neurosci 14 (2003) 207-216
20. Chalimoniuk M., and Langfort J. The effect of subchronic, intermittent L-DOPA treatment on neuronal nitric oxide synthase and soluble guanylyl cyclase expression and activity in the striatum and midbrain of normal and MPTP-treated mice. Neurochem Int 50 (2007) 821-833
21. Chalimoniuk M., and Stepien A. Influence of the therapy with pergolide mesylate plus L-DOPA and with L-DOPA alone on serum cGMP level in PD patients. Pol J Pharmacol 56 (2004) 647-650
22. Chase T.N., Oh J.D., and Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol 247 (2000) 36-42
23. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
24. De Oliveira C.L., Del-Bel E.A., and Guimarães F.S. Effects of L-NOARG on plus-maze performance in rats. Pharmacol Biochem Behav 56 (1997) 55-59
25. Dekundy A., Lundblad M., Danysz W., and Cenci M.A. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179 (2007) 76-89
26. Del-Bel E.A., Guimarães F.S., Bermudez-Echeverry M., Gomes M.Z., Schiaveto-de-Souza A., Padovan-Neto F., Tumas V., Barion-Cavalcanti A.P., Lazzarini M., Nucci-da-Silva L.P., and de Paula-Souza D. Role of nitric oxide on motor behavior. Cell Mol Neurobiol 25 (2005) 371-392
27. Del-Bel E.A., Padovan-Neto F.E., Tumas V., Gomes M.Z., and Dias-de-Oliveira E. Nitric oxide modulates the enhanced behavioral response to L-DOPA following repeated administration in the 6-OHDA-lesioned rat. J Physiol 565P (2006) PC68
28. Del-Bel E.A., da Silva C.A., Guimaraes F.S., and Bermudez-Echeverry M. Catalepsy induced by intrastriatal administration of nitric oxide synthase inhibitors in rats. Eur J Pharmacol 485 (2004) 175-181
29. Di Matteo V., Benigno A., Pierucci M., Giuliano D.A., Crescimanno G., Esposito E., and Di Giovanni G. 7-Nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study. Ann N Y Acad Sci 1089 (2006) 462-471
30. Dwyer M.A., Bredt D.S., and Snyder S.H. Nitric-oxide synthase-irreversible inhibition by l-NG-nitroarginine in brain in vitro and in vivo. Biochem Biophys Res Commun 176 (1991) 1136-1141
31. Eliasson M.J.L., Blackshaw S., Schell M.J., and Snyder S.H. Neuronal nitric oxide synthase alternatively spliced forms: prominent functional localizations in the brain. Proc Natl Acad Sci U S A 94 (1997) 3396-3401
32. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 23 (2008) S497-S508
33. Garthwaite J. Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci 27 (2008) 2783-2802
34. Goetz C.G., Damier P., Hicking C., Laska E., Muller T., Olanow C.W., Rascol O., and Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial. Mov Disord 22 (2007) 179-186
35. Gomes M.Z., Raisman-Vozari R., and Del-Bel E.A. A nitric oxide synthase inhibitor decreases 6-OHDA effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. Brain Res 1203 (2008) 160-169
36. Gomes M.Z., and Del-Bel E.A. Effects of electrolytic and 6-OHDA lesions of rat nigrostriatal pathway on NO-synthase and NADPH-d. Brain Res Bull 62 (2003) 107-115
37. Grace A.A. Physiology of the normal and dopamine-depleted basal ganglia: Insights into levodopa pharmacotherapy. Mov Disord 23 (2008) 560-569
38. Gyurko R., Leupen S., and Huang P.L. Deletion of exon 6 of the neuronal nitric oxide synthase gene in mice results in hypogonadism and infertility. Endocrinology 143 (2002) 2767-2774
39. Henry B., Crossman A.R., and Brotchie J.M. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-OHDA lesioned rat model of Parkinson's disease. Exp Neurol 151 (1998) 334-342
40. Itokawa K., Ohkuma A., Araki N., Tamura N., and Shimazu K. Effect of L-DOPA on nitric oxide production in striatum of freely mobile mice. Neurosci Lett 402 (2006) 142-144
41. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9 (2008) 665-677
42. Lane E., and Dunnett S. Animal models of Parkinson's disease and L-DOPA induced dyskinesia: how close are we to the clinic?. Psychopharmacology 199 (2008) 303-312
43. Langnaese K., Richter K., Smalla K.H., Krauss M., Thomas U., Wolf G., and Laube G. Splice-isoform specific immunolocalization of neuronal nitric oxide synthase in mouse and rat brain reveals that the PDZ-complex-building nNOS alpha beta-finger is largely exposed to antibodies. Dev Neurobiol 67 (2007) 422-437
44. Leiper J., and Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 43 (1999) 542-548
45. Lindgren H.S., Rylander D., Ohlin K.E., Lundblad M., and Cenci M.A. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res 177 (2007) 150-159
46. Lundblad N., Usiello A., Carta M., Hakansson K., Fisone G., and Cenci M.A. Pharmacological validation of a mouse model of L-DOPA-induced dyskinesia. Exp Neurol 194 (2005) 66-75
47. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15 (2002) 120-132
48. MacAllister R.J., Parry H., Kimoto M., Ogawa T., Russell R.J., Hodson H., Whitley G.S., and Vallance P. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 119 (1996) 1533-1540
49. Monville C., Torres E.M., and Dunnett S.B. Validation of the L-DOPA-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res Bull 68 (2005) 16-23
50. Morissette M., Dridi M., Calon F., Hadj Tahar A., Meltzer L.T., Bédard P.J., and Di Paolo D.T. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov Disord 21 (2006) 9-17
51. Mura A., Mintz M., and Feldon J. Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system. Exp Neurol 177 (2002) 252-264
52. Murray-Rust J., Leiper J., McAlister M., et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 8 (2001) 679-683
53. Nutt J.G. Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease. Exp Neurol 184 (2003) 9-13
54. Obeso J.A., Rodríguez-Oroz M.C., Benitez-Temino B., Blesa F.J., Guridi J., Marin C., and Rodriguez M. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord 23 (2008) 548-559
55. Olanow C.W. Levodopa/dopamine replacement strategies in Parkinson's disease: future directions. Mov Disord 23 (2008) 613-622
56. Papa S.M., Engber T.M., Kask A.M., and Chase T.N. Motor fluctuations in L-DOPA treated parkinsonian rats-relation to lesion extent treatment duration. Brain Res 662 (1994) 69-74
57. Pavon N., Martin A.B., Mendialdua A., and Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59 (2006) 64-74
58. Paxinos G., and Watson W. The rat brain in stereotaxic coordinates. 4th ed. (1998), Academic Press, San Diego
59. Petros A., Lamb G., Leone A., Moncada S., Bennett D., and Vallance P. Effects of a nitric-oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28 (1994) 34-39
60. Rees D.D. Role of nitric oxide in the vascular dysfunction of septic shock. Biochem Soc Trans 23 (1995) 1025-1029
61. Sammut S., Dec A., Mitchell D., Linardakis J., Ortiguela M., and West A.R. Phasic dopaminergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D-1/5 receptor-dependent mechanism. Neuropsychopharmacology 31 (2006) 493-505
62. Sanchez J.J., Abreu P., and Gonzalez M.C. Sodium nitroprusside stimulates L-DOPA release from striatal tissue through NO and cGMP. Eur J Pharmacol 438 (2002) 79-83
63. Santini E., Valjent E., and Fisone G. Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J 275 (2008) 1392-1399
64. Silverdale M.A., Fox T.H., Crossman A.R., and Brotchie J.M. Potential nondopaminergic drugs for Parkinson's disease. Adv Neurol 91 (2003) 273-291
65. St-Pierre J.A., and Bedard P.J. Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine. Eur J Pharmacol 272 (1995) 123-129
66. Taylor J.L., Bishop C., and Walker P.D. Dopamine D-1 and D-2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol Biochem Behav 81 (2005) 887-893
67. Trabace L., and Kendrick K.M. Nitric oxide can differentially modulate striatal neurotransmitter concentrations via soluble guanylate cyclase and peroxynitrite formation. J Neurochem 75 (2000) 1664-1674
68. Traystman R.J., Moore L.E., Helfaer M.A., Davis S., Banasiak K., Williams M., and Hurn P.D. Nitro-l-arginine analogs-dose-related and time-related nitric-oxide synthase inhibition in brain. Stroke 26 (1995) 864-868
69. Truong L., Allbutt H., Kassiou M., and Henderson J.M. Developing a preclinical model of Parkinson's disease: A study of behaviour in rats with graded 6-OHDA lesions. Behav Brain Res 169 (2006) 1-9
70. Vallance P. Nitric oxide: therapeutic opportunities. Fundam Clin Pharmacol 17 (2003) 1-10
71. Vincent S.R., and Johansson O. Striatal neurons containing both somatostatin pancreatic and avian APP-like immunoreactivities and NADPH-diaphorase activity-a light and electron-microscopic study. J Comp Neurol 217 (1983) 264-270
72. Vincent S.R., and Kimura H. Histochemical mapping of nitric-oxide synthase in the rat-brain. Neuroscience 46 (1992) 755-784
73. West A.R., and Grace A.A. The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity states and electrophysiological properties of striatal medium spiny neurons recorded in vivo. J Neurosci 24 (2004) 1924-1935
74. West A.R., Galloway M.P., and Grace A.A. Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms. Synapse 44 (2002) 227-245
75. West A.R., and Grace A.A. Striatal nitric oxide signaling regulates the neuronal activity of midbrain dopamine neurons in vivo. J Neurophysiol 83 (2000) 1796-1808
76. West A.R., and Galloway M.P. Nitric oxide and potassium chloride facilitated striatal dopamine efflux in vivo: role of calcium-dependent release mechanisms. Neurochem Int 33 (1998) 493-501
77. West A.R., and Galloway M.P. Endogenous nitric oxide facilitates striatal dopamine and glutamate efflux in vivo: role of ionotropic glutamate receptor-dependent mechanisms. Neuropharmacology 36 (1997) 1571-1581